


Third Edition

HEMATOLOGY- ONCOLOGY THERAPY



**Mc
Graw
Hill**

**Michael M. Boyiadzis
Tito Fojo**

HEMATOLOGY-ONCOLOGY THERAPY

THIRD EDITION



MICHAEL M. BOYIADZIS, MD, MHSc

Professor of Medicine and Clinical and Translational Science
Department of Medicine, Division of Hematology-Oncology
University of Pittsburgh School of Medicine
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

TITO FOJO, MD, PhD

Professor of Medicine
Department of Medicine, Division of Hematology-Oncology
Columbia University
Herbert Irving Comprehensive Cancer Center
New York, New York

**Mc
Graw
Hill**

New York Chicago San Francisco Athens London Madrid
Mexico City Milan New Delhi Singapore Sydney Toronto

Copyright © 2022 by McGraw Hill. All rights reserved. Printed in China. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher.

1 2 3 4 5 6 7 8 9 DSS 26 25 24 23 22 21

ISBN 978-1-260-11740-0

MHID 1-260-11740-5

Notice

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encourage to confirm the information contained herein with other sources. For example and in particular, readers are advised to check product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

This book was set in Centaur MT Std by Thomson Digital.

The editors were Jason Malley, Karen Edmonson and Harriet Lebowitz.

The production supervisor was Richard Ruzicka.

The book designer was Eve Siegel.

Project management was provided by Sudhi Singh, Thomson Digital.

Cover art: Chryso Boyiatzi

The cover designer was W2 Design.

Library of Congress Control Number: 2020951231

McGraw Hill books are available at special quantity discounts to use as premiums and sales promotions, or for use in corporate training programs. To contact a representative, please visit the Contact Us pages at www.mhprofessional.com.

To the patients our profession has the privilege to serve, and to our colleagues whose compassionate care and research efforts continue to extend the spectrum of hope.

Contents

Contents: Regimens Listed by Type of Cancer	ix	14. Endometrial Cancer	815
Authors	xxxii	<i>Don S. Dizon, MD, FACP, FASCO</i>	
Preface	xxxix	15. Esophageal Cancer	835
SECTION I: TREATMENT REGIMENS	1	<i>Sunnie Kim, MD and John Marshall, MD</i>	
1. Acute Lymphoblastic Leukemia	3	16. Gastric Cancer	862
<i>Michael M. Boyiadzis, MD, MHSc, Ivan Aksentjevich, MD, and Mark R. Litzow, MD</i>		<i>Jonas W. Feilchenfeldt, MD and Manish A. Shah, MD</i>	
2. Acute Myeloid Leukemia	108	17. Gestational Trophoblastic Neoplasia	923
<i>Michael M. Boyiadzis, MD, MHSc, Ivan Aksentjevich, MD, and Martin S. Tallman, MD</i>		<i>John R. Lurain, MD</i>	
3. Adrenocortical Cancer	184	18. Hairy Cell Leukemia	936
<i>Tito Fojo, MD, PhD</i>		<i>Maximilian Stabl, MD and Martin S. Tallman, MD</i>	
4. Anal Cancer	194	19. Head and Neck Cancers	952
<i>Benjamin A. Weinberg, MD, Irfan Jawed, MD, and John Marshall, MD</i>		<i>Pol Specenier, MD, PhD and JB Vermorken, MD, PhD</i>	
5. Biliary: Gallbladder Cancer and Cholangiocarcinoma	219	20. Hepatocellular Carcinoma	1035
<i>Tim Greten, MD, PhD and Susanna Ulabannan, MD, MMed</i>		<i>Tim Greten, MD, PhD and Cecilia Monge, MD</i>	
6. Bladder Cancer	245	21. HIV-Related Malignancies	1109
<i>Andrea B. Apolo, MD and Dean Bajorin, MD</i>		<i>Kathryn Lurain, MD, MPH, Robert Yarchoan, MD, and Thomas S. Uldrick, MD, MS</i>	
7. Breast Cancer	304	22. Hodgkin Lymphoma	1138
<i>Rachel Yung, MD, Nancy E. Davidson, MD, and Jennifer M. Specht, MD</i>		<i>Michael Fuchs, MD and Völker Diehl, MD</i>	
8. Carcinoma of Unknown Primary	510	23. Lung Cancer	1176
<i>David R. Spiegel, MD and F. Anthony Greco, MD</i>		<i>Enriqueta Felip, MD, PhD and Rafael Rosell, MD</i>	
9. Central Nervous System Cancers	525	24. Melanoma	1341
<i>Lyndon Kim, MD and Howard A. Fine, MD</i>		<i>Ahmad A. Tarbini, MD, PhD and John M. Kirkwood, MD</i>	
10. Cervical Cancer	614	25. Mesothelioma	1413
<i>Peter G. Rose, MD</i>		<i>Mohamed M. Azab, MD, Tamarah A. Al-Dawoodi, MD, and Nicholas J. Vogelzang, MD</i>	
11. Chronic Lymphocytic Leukemia	645	26. Multiple Myeloma	1455
<i>Dhaval Mehta, MD and Kanti Rai, MD</i>		<i>Giada Bianchi, MD, Aldo Roccaro, MD, PhD, Irene M. Ghobrial, MD, and Kenneth C. Anderson, MD</i>	
12. Chronic Myeloid Leukemia	704	27. Myelodysplastic Syndromes	1640
<i>Michael W.N. Deininger, MD, PhD, Diana Brewer, PA, and Brian J. Druker, MD</i>		<i>Michael M. Boyiadzis, MD, MHSc and Neal S. Young, MD</i>	
13. Colorectal Cancer	733	28. Myeloproliferative Neoplasms	1666
<i>Jennifer M. Duff, MD, Jason Starr, DO, and Carmen Joseph Allegra, MD</i>		<i>Naseema Gangat, MD and Ayalew Tefferi, MD</i>	
		29. Neuroendocrine Tumors	1713
		<i>Sara Ekeblad, MD, PhD and Britt Skogseid, MD, PhD</i>	

VI CONTENTS

30. Non-Hodgkin Lymphoma <i>Jennifer E. Amengual, MD and Philippe Armand, MD, PhD</i>	1742	40. Tissue-Agnostic Therapies <i>Tito Fojo, MD, PhD and Susan E. Bates, MD</i>	2534
31. Ovarian Cancer <i>Kunle Odunsi, MD, PhD and J. Brian Szender MD, MPH</i>	1955	41. Vaginal Cancer <i>Leslie Boyd, MD and Franco Muggia, MD</i>	2559
32. Pancreatic Cancer <i>Susan E. Bates, MD and Daniel D. Von Hoff, MD, FACP</i>	2019	SECTION II: ANTIEMETICS, GROWTH FACTORS, AND DRUG PREPARATION	2569
33. Pheochromocytoma <i>Karel Pacak, MD, PhD, DSc and Tito Fojo, MD, PhD</i>	2070	42. Prophylaxis and Treatment of Chemotherapy- and Radiation-Induced Nausea and Vomiting <i>Thomas E. Hughes, PharmD, BCOP</i>	2571
34. Prostate Cancer <i>Fatima Karzai, MD, Wenhui Zhu, MD, PhD, and William L. Dabut, MD</i>	2076	43. Indications for Growth Factors in Hematology-Oncology <i>Gerard P. Mascara, PharmD, BCOP and Tito Fojo, MD, PhD</i>	2582
35. Renal Cell Cancer <i>David H. Aggen, MD, PhD and Martin H. Voss, MD</i>	2130	44. Guidelines for Chemotherapy Dosage Adjustment <i>Timothy J. George, PharmD, BCOP, Gerard P. Mascara, PharmD, BCOP, and Tito Fojo, MD, PhD</i>	2602
36. Sarcomas <i>Brigitte Widemann, MD, Srivandana Akshintala, MBBS, MPH, and Jean-Yves Blay, MD</i>	2241	45. Drug Preparation and Administration <i>Gerard P. Mascara, PharmD, BCOP</i>	2641
37. Testicular Cancer <i>Darren R. Feldman, MD</i>	2466	Index	2829
38. Thymic Malignancies <i>Chul Kim, MD, MPH and Giuseppe Giaccone, MD, PhD</i>	2482		
39. Thyroid Cancer <i>Livia Lamartina, MD, PhD</i>	2499		

Online Only Chapters

AccessHemOnc.com

SECTION III: SUPPORTIVE CARE, COMPLICATIONS, AND SCREENING

46. Antineoplastic Drugs: Preventing and Managing Extravasation <i>Khilna Patel, PharmD, BCOP, MBA</i>		51. Catheter-Related Bloodstream Infections: Management and Prevention <i>Naomi P. O'Grady, MD</i>	
47. Indications for Bone-Modifying Agents in Hematology-Oncology <i>Lisa Cordes, PharmD, BCACP, BCOP and Tito Fojo, MD, PhD</i>		52. Venous Catheter-Related Thrombosis <i>Roy E. Smith, MD, MS</i>	
48. Transfusion Therapy <i>Asbok Nambiar, MD and Joseph E. Kiss, MD</i>		53. Complications and Follow-Up After Hematopoietic Cell Transplantation <i>Mariam Nawas, MD, Satyajit Kosuri, MD, Juan C. Gea-Banacloche, MD, and Michael R. Bishop, MD</i>	
49. Oncologic Emergencies <i>Tito Fojo, MD, PhD</i>		54. Radiation Complications <i>Emily S. Wég, MD, Ramesh Rengan, MD, PhD, EASTRO</i>	
50. Fever and Neutropenia <i>Mary Czech, MD and Juan C. Gea-Banacloche, MD</i>		55. Cancer Pain: Assessment and Management <i>Justin R. Price, MD and Ann Berger, MSN, MD</i>	
		56. Hospice Care and End-of-Life Issues <i>Christine D. Hudak, MD and Charles F. von Gunten, MD, PhD</i>	

57. Cancer Screening

*Kathleen A. Calzone, PhD, RN, APNG, FAAN and
Sheila Prindiville, MD, MPH*

58. Genetics of Common Inherited Cancer Syndromes

*Kathleen A. Calzone, PhD, RN, APNG, FAAN and
Sheila Prindiville, MD, MPH*

SECTION IV: SELECTED HEMATOLOGIC DISEASES**59. von Willebrand Disease**

Pier M. Mannucci, MD

60 Hemophilia

Craig D. Seaman, MD, MS and Margaret V. Ragni, MD, MPH

61. The Hypercoagulable State

Jeffrey I. Zwicker, MD and Kenneth A. Bauer, MD

62. Heparin-Induced Thrombocytopenia

David L. Dinguid, MD

63. Iron Deficiency Anemia

Roy E. Smith, MD, MS

64. Autoimmune Hemolytic Anemia

Sigbjørn Berentsen, MD, PhD

65. Sickle Cell Disease: Acute Complications

*Ramasubramanian Kalpathi, MD, Enrico M. Novelli, MD, MS,
Mark T. Gladwin, MD, and Griffin P. Rodgers, MD, MACP*

66. Aplastic Anemia

Bhavisha Patel, MD and Neal S. Young, MD

**67. Thrombotic Thrombocytopenic Purpura/
Hemolytic Uremic Syndrome**

Marie Scully, MD

68. Idiopathic Thrombocytopenic Purpura

Megan Askew, MD and Cindy Neunert, MD MSCS

69. Hemochromatosis

James C. Barton, MD

Contents: Regimens Listed by Type of Cancer

Chapter 1. ACUTE LYMPHOBLASTIC LEUKEMIA

Adolescent/Young Adult

CALGB 10403 Induction (Course I)	11
CALGB 10403 Extended Induction (Course IA)	17
CALGB 10403 Consolidation (Course II)	20
CALGB 10403 Interim Maintenance (Course III)	24
CALGB 10403 Delayed Intensification (Course IV)	28
CALGB 10403 Maintenance (Course V)	32

Adult ALL Regimens

Larson	36
Hyper-CVAD	43
Linker	48
MRC UKALL XII/ECOG E2993	55
Hyper-CVAD + Dasatinib	61
Hyper-CVAD + Imatinib	67

Minimal Residual Disease-Positive ALL

Blinatumomab	73
--------------	----

Relapsed/Refractory ALL

Blinatumomab	81
Inotuzumab Ozogamicin	90
Mini-Hyper-CVD + Inotuzumab Ozogamicin	95
Liposomal Vincristine Sulfate	104
Nelarabine	106

Chapter 2. ACUTE MYELOID LEUKEMIA

Intensive Induction Therapy • First-Line

Cytarabine + Daunorubicin	114
Cytarabine + Idarubicin	116

Intensive Post-Remission Therapy

High-Dose Cytarabine	117
----------------------	-----

Intensive Induction Therapy and Post-remission Therapy • First-Line

Daunorubicin + Cytarabine + Gemtuzumab Ozogamicin	119
Daunorubicin + Cytarabine + Midostaurin	126
CPX-351 (Cytarabine + Daunorubicin) Liposome	131

Low-Intensity Therapy • First-Line

Venetoclax + Decitabine	135
Venetoclax + Azacitidine	139
Venetoclax + Low-Dose Cytarabine	143
Glasdegib + Low-Dose Cytarabine	143
Ivosidenib	150
Gemtuzumab Ozogamicin	154

X CONTENTS: REGIMENS LISTED BY TYPE OF CANCER

Subsequent Therapy	
Gilteritinib	157
Ivosidenib	161
Enasidenib	164
Gemtuzumab Ozogamicin	166
Acute Promyelocytic Leukemia • First Line • Low Risk	
Tretinoin (All Trans-Retinoic Acid) + Arsenic Trioxide	169
Acute Promyelocytic Leukemia • First Line • High Risk	
Tretinoin (All Trans-Retinoic Acid) + Arsenic Trioxide + Gemtuzumab Ozogamicin	173
Tretinoin (All Trans-Retinoic Acid) + Idarubicin	177
Acute Promyelocytic Leukemia • Relapsed	
Arsenic Trioxide	181
Chapter 3. ADRENOCORTICAL CANCER	
Adjuvant or Metastatic	
Mitotane	187
Metastatic	
Cisplatin + Mitotane	189
Etoposide + Doxorubicin + Cisplatin + Mitotane (EDP-M)	190
Streptozocin + Mitotane (SZ-M)	192
Doxorubicin	Online
Chapter 4. ANAL CANCER	
Locoregional Disease + Chemoradiation	
Mitomycin + Fluorouracil + Radiation Therapy	198
Fluorouracil + Cisplatin + Radiation Therapy	200
Metastatic • First-Line	
Carboplatin + Paclitaxel	202
Cisplatin + Fluorouracil by Continuous Intravenous Infusion	205
Metastatic • Subsequent Therapy	
Nivolumab	207
Pembrolizumab	213
Chapter 5. BILIARY: GALLBLADDER CANCER AND CHOLANGIOCARCINOMA	
Adjuvant	
Capecitabine	225
Advanced Disease	
Gemcitabine + Cisplatin	230
Gemcitabine + Oxaliplatin (GemOx)	232
Gemcitabine + Capecitabine	233
Capecitabine + Oxaliplatin	234
Gemcitabine + Nab-Paclitaxel + Cisplatin	235
Gemcitabine	Online
Mitomycin + Capecitabine	Online
Advanced Disease • Subsequent Therapy	
Pemigatinib	240

Chapter 6. BLADDER CANCER

Neoadjuvant

Gemcitabine + Cisplatin (GC)	248
Methotrexate + Vinblastine + Doxorubicin + Cisplatin (MVAC) Before Radical Cystectomy	249
Cisplatin, Methotrexate, And Vinblastine	Online

Metastatic • First-Line

Gemcitabine + Cisplatin (GC)	250
High-Dose (HD) Or Dose-Dense (DD) Methotrexate, Vinblastine, Doxorubicin, And Cisplatin	251
Gemcitabine + Carboplatin	254
Methotrexate + Vinblastine + Doxorubicin + Cisplatin (MVAC)	256

Metastatic • First-Line • Subsequent Therapy

Atezolizumab	258
Pembrolizumab	266

Metastatic • Subsequent Therapy

Nivolumab	275
Avelumab	282
Durvalumab	288
Erdafitinib	295
Enfortumab Vedotin	300

Chapter 7. BREAST CANCER

Adjuvant • Hormone-Receptor Positive • Premenopausal

Exemestane Plus Ovarian Suppression	322
-------------------------------------	-----

Adjuvant • HER2-Negative

Docetaxel + Doxorubicin + Cyclophosphamide (TAC)	324
Dose-Dense Doxorubicin + Cyclophosphamide, Then Paclitaxel Every 2 Weeks (DDAC → P)	325
Doxorubicin + Cyclophosphamide, Then Weekly Paclitaxel (AC → P)	327
Docetaxel + Cyclophosphamide (TC) Every 3 Weeks × 4 Cycles	330
Cyclophosphamide + Epirubicin + Fluorouracil (FEC) × 4 Cycles → Weekly Paclitaxel × 8 Cycles	332
Cyclophosphamide + Epirubicin + Fluorouracil (FEC) × 3 Cycles → Docetaxel × 3 Cycles	335
Capecitabine	338
Cyclophosphamide + Epirubicin + Fluorouracil (FEC 100)	Online
Cyclophosphamide + Methotrexate + Fluorouracil (CMF; Oral)	Online
Doxorubicin + Cyclophosphamide (AC)	Online
Doxorubicin + Cyclophosphamide Then Docetaxel Every 3 Weeks (AC → T)	Online

Adjuvant • HER2-Positive

Docetaxel + Trastuzumab Followed by Cyclophosphamide + Epirubicin + Fluorouracil (FEC)	342
Paclitaxel + Trastuzumab	346
Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (TCHP)	349
Docetaxel + Trastuzumab + Pertuzumab (DHP)	355
Weekly Paclitaxel + Trastuzumab + Pertuzumab	360
Ado-Trastuzumab Emtansine	365
Neratinib	369

Adjuvant • Neoadjuvant • HER2-Positive

Docetaxel + Carboplatin + Trastuzumab (TCH)	373
Doxorubicin + Cyclophosphamide (AC), Then Paclitaxel + Trastuzumab, Then Trastuzumab Alone	377
Doxorubicin + Cyclophosphamide (AC) Followed By Docetaxel With Trastuzumab (TH) (AC → TH)	381

XII CONTENTS: REGIMENS LISTED BY TYPE OF CANCER

Neoadjuvant • HER2-Positive

Neoadjuvant Fluorouracil + Epirubicin + Cyclophosphamide (FEC) Then Neoadjuvant Docetaxel + Trastuzumab + Pertuzumab (DHP) Then Adjuvant Trastuzumab	385
Neoadjuvant Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (TCHP) Then Adjuvant Trastuzumab	392
Neoadjuvant Docetaxel + Trastuzumab + Pertuzumab (DHP) Then Adjuvant Fluorouracil + Epirubicin + Cyclophosphamide Then Adjuvant Trastuzumab	Online

Neoadjuvant • Triple-Negative

Carboplatin + Paclitaxel Then Dose-Dense Doxorubicin + Cyclophosphamide	398
---	-----

Hormonal Therapy Agents

405

Metastatic • Hormone Receptor Positive • HER2-Negative

Palbociclib + Letrozole	407
Palbociclib + Fulvestrant	411
Ribociclib + Letrozole	415
Abemaciclib + Non-Steroidal Aromatase Inhibitor	419
Abemaciclib + Fulvestrant	423
Everolimus + Exemestane	Online
Abemaciclib	Online

Metastatic • Hormone Receptor-Positive • HER2-Negative • PIK3CA-Mutated

Alpelisib + Fulvestrant	427
-------------------------	-----

Metastatic

Doxorubicin, Every 3 Weeks	432
Weekly Paclitaxel	433
Paclitaxel Every 3 Weeks	434
Weekly Docetaxel	436
Docetaxel Every 3 Weeks	437
Albumin-Bound Paclitaxel	438
Capecitabine	440
Gemcitabine	442
Eribulin Mesylate	444
Doxorubicin + Cyclophosphamide (AC)	446
Cyclophosphamide + Epirubicin + Fluorouracil	448
Cyclophosphamide + Methotrexate + Fluorouracil	450
Docetaxel + Capecitabine	452
Paclitaxel and Gemcitabine	455
Weekly Doxorubicin or Epirubicin	Online
Liposomal Doxorubicin	Online
Weekly Vinorelbine	Online
Ixabepilone	Online
Paclitaxel Plus Bevacizumab	Online
Ixabepilone + Capecitabine	Online

Metastatic • HER2-Positive • Hormone Receptor-Positive

Lapatinib + Trastuzumab + Aromatase Inhibitor	457
---	-----

Metastatic • HER2-Positive

Trastuzumab	462
Docetaxel + Trastuzumab + Pertuzumab	464
Docetaxel Every 3 Weeks + Weekly Trastuzumab	467
Weekly Docetaxel + Trastuzumab	469

Trastuzumab + Paclitaxel, Every 3 Weeks	471
Weekly Paclitaxel + Trastuzumab	473
Ado-Trastuzumab Emtansine	476
Capecitabine + Trastuzumab	479
Tucatinib + Capecitabine + Trastuzumab	481
Fam-Trastuzumab Deruxtecan	486
Lapatinib + Capecitabine	Online
Weekly Vinorelbine + Trastuzumab	Online
Everolimus + Vinorelbine + Trastuzumab	Online
Neratinib + Capecitabine	Online
Metastatic • Triple-Negative	
Single-Agent Platinum (Carboplatin or Cisplatin)	490
Atezolizumab + Nab-Paclitaxel	493
Sacituzumab Govitecan	501
Metastatic • Germline BRCA Mutation • HER2-Negative	
Olaparib	505
Talazoparib	507
Chapter 8. CARCINOMA OF UNKNOWN PRIMARY	
First-Line	
Paclitaxel + Carboplatin	513
Paclitaxel + Carboplatin + Etoposide	516
Gemcitabine + Irinotecan	519
Subsequent Therapy	
Oxaliplatin + Capecitabine	523
Chapter 9. CENTRAL NERVOUS SYSTEM CANCERS	
Glioma, Newly Diagnosed	
Procarbazine, Lomustine, and Vincristine After Radiation	537
Anaplastic Oligodendroglioma and Anaplastic Oligoastrocytoma, Newly Diagnosed	
Procarbazine, Lomustine (CCNU), and Vincristine (PCV) after Radiation	540
Procarbazine, Lomustine, And Vincristine before Radiation	543
Anaplastic Astrocytoma, Newly Diagnosed	
Temozolomide	547
Radiation Plus Either Temozolomide, Lomustine, or Carmustine	551
Glioblastoma, Newly Diagnosed	
Temozolomide With Radiation Therapy	555
Lomustine + Temozolomide	Online
Glioblastoma, Recurrent	
Bevacizumab ± Irinotecan	556
Lomustine (CCNU)	559
Lomustine And Bevacizumab	560
Carmustine (BCNU)	Online
Carboplatin	Online
Primary CNS Lymphoma, Newly Diagnosed	
High-Dose Methotrexate	563
High-Dose Methotrexate and Rituximab With Deferred Radiotherapy	565

XIV CONTENTS: REGIMENS LISTED BY TYPE OF CANCER

Induction Rituximab, Methotrexate, and Temozolomide, Followed by Whole-Brain Radiotherapy and Postirradiation Temozolomide	569
Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation, Reduced-Dose Whole-Brain Radiotherapy, and Cytarabine (R-MPV → RT + C)	574
Primary CNS Lymphoma, Recurrent	
Pemetrexed	579
High-Dose Cytarabine	581
Ibrutinib	583
Nivolumab	587
Topotecan	Online
Meningioma, Recurrent	
Long-Acting Octreotide Acetate	592
Bevacizumab	595
Bevacizumab + Everolimus	597
Interferon Alfa	Online
Hydroxyurea	Online
Sunitinib	Online
Everolimus + Long-Acting Octreotide Acetate	Online
Medulloblastoma, Newly Diagnosed	
Craniospinal Chemoradiotherapy Followed By Adjuvant Cisplatin + Vincristine + Lomustine	602
Craniospinal Chemoradiotherapy Followed By Adjuvant Cisplatin + Vincristine + Cyclophosphamide	606
Craniospinal Chemoradiotherapy Followed By Adjuvant Cisplatin + Lomustine + Vincristine + Cyclophosphamide	610
Cisplatin + Etoposide + Cyclophosphamide Followed by Craniospinal Radiotherapy ± Maintenance Chemotherapy	Online
Medulloblastoma, Recurrent	
Cyclophosphamide + Doxorubicin + Vincristine	Online
Bevacizumab + Irinotecan + Temozolomide	Online
Celecoxib + Etoposide + Isotretinoin + Temozolomide	Online
Vismodegib	Online
Chapter 10. CERVICAL CANCER	
Concomitant Chemoradiation	
Concurrent Radiation Therapy + Chemotherapy/Weekly Cisplatin	617
Concurrent Radiation Therapy + Chemotherapy/Cisplatin + Fluorouracil	Online
Concurrent Radiation Therapy + Chemotherapy/Weekly Carboplatin	Online
Advanced/Recurrent • First-Line	
Cisplatin + Paclitaxel	619
Paclitaxel + Carboplatin	621
Cisplatin + Topotecan	624
Cisplatin + Gemcitabine	626
Paclitaxel + Topotecan ± Bevacizumab	628
Paclitaxel + Cisplatin + Bevacizumab	633
Cisplatin + Vinorelbine	Online
Cisplatin + Irinotecan	Online
Advanced/Recurrent • Subsequent Therapy	
Pembrolizumab	638

Chapter 11. CHRONIC LYMPHOCYTIC LEUKEMIA

First-Line

Ibrutinib	648
Ibrutinib + Rituximab	652
Venetoclax + Obinutuzumab	657
Fludarabine + Cyclophosphamide + Rituximab	665
Bendamustine + Rituximab	670
Fludarabine + Rituximab	675

Subsequent Therapy

Venetoclax	677
Venetoclax + Rituximab	684
Idelalisib + Rituximab	691
Acalabrutinib	697
Ibrutinib	700

Chapter 12. CHRONIC MYELOID LEUKEMIA

Initial Therapy

Imatinib	714
Dasatinib	716
Nilotinib	718
Bosutinib	720

Subsequent Therapy

Ponatinib	722
Omacetaxine Mepesuccinate	727
Hydroxyurea	729
Interferon	730

Chapter 13. COLORECTAL CANCER

Adjuvant

mFOLFOX-6	737
Capecitabine + Oxaliplatin (XELOX)	740
Capecitabine	744
Bolus Fluorouracil + Leucovorin	Online

Metastatic • First-Line

Leucovorin + Infusional Fluorouracil + Oxaliplatin (FOLFOX)	746
mFOLFOX6 ± Bevacizumab	749
Capecitabine + Oxaliplatin (XELOX) ± Bevacizumab	753
Cetuximab + FOLFOX4	757
Panitumumab + mFOLFOX6	761
Leucovorin + Infusional Fluorouracil + Irinotecan (FOLFIRI)	764
FOLFIRI + Bevacizumab	767
Cetuximab + FOLFIRI	772
Panitumumab + FOLFIRI	776
FOLFOXIRI + Bevacizumab	Online

Metastatic

Modified de Gramont 5-Fluorouracil + Leucovorin	780
Capecitabine	782
Bolus Fluorouracil + Leucovorin (Roswell Park Regimen)	Online

XVI CONTENTS: REGIMENS LISTED BY TYPE OF CANCER

Metastatic • Subsequent Therapy	
Bevacizumab + FOLFIRI or FOLFOX4 after First Progression on Bevacizumab	786
Infusional Fluorouracil	791
Trifluridine/Tipiracil (TAS-102)	792
Panitumumab + Best Supportive Care	795
Nivolumab	798
Pembrolizumab	804
Ziv-aflibercept + FOLFIRI	Online
FOLFIRI + Ramucirumab	Online
Single-agent Irinotecan (CPT-11)	Online
Regorafenib	Online
Rectal cancer	
Fluorouracil + Radiation	811
Chemoradiotherapy With Capecitabine	812
Chapter 14. ENDOMETRIAL CANCER	
Adjuvant	
Cisplatin with Concurrent Pelvic Radiation Therapy Followed by Carboplatin + Paclitaxel	819
Metastatic	
Paclitaxel + Carboplatin (TC)	824
Pembrolizumab + Lenvatinib	826
Chapter 15. ESOPHAGEAL CANCER	
Preoperative Chemoradiotherapy	
Fluorouracil + Cisplatin + Radiation	838
Oxaliplatin + Protracted Infusion Fluorouracil and External Beam Radiation Therapy (EBRT) Prior to Surgery	840
Carboplatin + Paclitaxel + Concurrent Radiotherapy	841
Metastatic • First-Line	
Cisplatin + Capecitabine	844
Oxaliplatin + Fluorouracil + Leucovorin (FOLFOX)	847
Cisplatin + Capecitabine ± Trastuzumab	849
Metastatic • Subsequent Therapy	
Ramucirumab + Paclitaxel	853
Pembrolizumab	856
Chapter 16. GASTRIC CANCER	
Locoregional Disease • Perioperative	
Fluorouracil + Leucovorin + Oxaliplatin + Docetaxel (FLOT)	866
Capecitabine + Oxaliplatin (CAPOX)	870
Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX)	873
Cisplatin + Fluorouracil (CF)	876
Locoregional Disease • Adjuvant	
Fluorouracil + Leucovorin + Radiation	879
Capecitabine And Oxaliplatin after D2 Gastrectomy	881
Metastatic Disease • First-Line	
Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) ± Trastuzumab	884
Capecitabine + Oxaliplatin (CAPOX) ± Trastuzumab	888

Cisplatin + Either Fluorouracil (CF) Or Capecitabine (CX) ± Trastuzumab	892
Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) ± Trastuzumab	897
Modified Docetaxel + Cisplatin + Fluorouracil (MDCF) ± Trastuzumab	901
Docetaxel + Cisplatin + Fluorouracil (DCF) ± Trastuzumab	Online
Metastatic Disease • Second-Line	
Ramucirumab + Paclitaxel	906
Paclitaxel	911
Irinotecan	913
Ramucirumab	Online
Docetaxel	Online
Metastatic Disease • Third-Line	
Pembrolizumab	916

Chapter 17. GESTATIONAL TROPHOBLASTIC NEOPLASIA

First-Line • Nonmetastatic • Low-Risk Metastatic	
Methotrexate	927
Methotrexate With Leucovorin	928
Dactinomycin	929
First-Line • High-Risk Metastatic	
Etoposide + Methotrexate + Dactinomycin + Cyclophosphamide + Vincristine (EMA/CO)	930
Refractory • High-Risk Metastatic • PSTT/ETT First-Line	
Etoposide + Cisplatin/Etoposide + Methotrexate + Dactinomycin (EP/EMA)	932
Paclitaxel + Cisplatin/Paclitaxel + Etoposide (TP/TE)	934

Chapter 18. HAIRY CELL LEUKEMIA

First-Line • Relapse	
Cladribine + Rituximab	939
Cladribine	941
Pentostatin	943
Second-Line	
Moxetumomab Pasudotox-tdfk	944
Rituximab	947
Vemurafenib	949

Chapter 19. HEAD AND NECK CANCERS

Concomitant Chemoradiation	
Cisplatin with Radiation Therapy	957
Cisplatin Alone with Radiation Therapy or Cisplatin + Fluorouracil with Radiation Therapy	959
Cisplatin + Paclitaxel with Radiation Therapy	962
Carboplatin + Fluorouracil with Radiation Therapy	964
Cisplatin with Radiation Therapy	966
Cetuximab + Radiation	970
Cisplatin with Radiation Therapy Followed by Cisplatin + Fluorouracil	Online
Locally Advanced • Induction Chemotherapy Followed by Chemoradiation	
Docetaxel + Cisplatin + Fluorouracil (TPF) or Cisplatin + Fluorouracil (PF) Followed by Chemoradiation	973
Docetaxel + Cisplatin + Fluorouracil (TPF) or Cisplatin + Fluorouracil (PF) Followed by Radiotherapy	978

XVIII CONTENTS: REGIMENS LISTED BY TYPE OF CANCER

Postoperative Chemoradiation	
Postoperative Chemoradiation with Cisplatin	981
Postoperative Chemoradiation with Cisplatin + Fluorouracil	983
Metastatic • PD-L1 CPS \geq 1	
Pembrolizumab	985
Metastatic	
Pembrolizumab + Platinum (Cisplatin or Carboplatin) + Fluorouracil	991
Cisplatin + Fluorouracil	999
Carboplatin + Fluorouracil	1002
Cisplatin or Carboplatin with Fluorouracil + Cetuximab	1005
Cisplatin + Paclitaxel or Cisplatin + Fluorouracil	1009
Paclitaxel + Carboplatin	1012
Docetaxel + Cisplatin	1014
Cisplatin	1016
Docetaxel	1017
Methotrexate	Online
Weekly Docetaxel	Online
Gefitinib or Erlotinib (Oral Epidermal Growth Factor Inhibitors)	Online
Metastatic • Platinum-Refractory	
Pembrolizumab	1019
Nivolumab	1025
Cetuximab	1031
Metastatic • Nasopharyngeal	
Gemcitabine + Cisplatin	1032
Chapter 20. HEPATOCELLULAR CARCINOMA	
Locoregional Therapy	
Chemoembolization with Doxorubicin	1045
Chemoembolization with Cisplatin	1049
DEB-TACE—Transarterial Chemoembolization (TACE) Using Drug-Eluting Beads (DEB)	1054
Unresectable Disease • First-Line	
Atezolizumab + Bevacizumab	1058
Sorafenib	1067
Lenvatinib	1074
Unresectable Disease • Subsequent Therapy	
Ramucirumab	1079
Cabozantinib	1083
Nivolumab	1087
Pembrolizumab	1094
Nivolumab + Ipilimumab	1101
Regorafenib	Online
Chapter 21. HIV-RELATED MALIGNANCIES	
Kaposi Sarcoma - First-Line • Systemic	
Liposomal Doxorubicin	1111
Paclitaxel	1113

Kaposi Sarcoma -Subsequent Therapy • Systemic	
Pomalidomide	1115
HIV-Related Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease	
Rituximab	1119
Rituximab + Liposomal Doxorubicin	1121
HIV-Related Lymphomas- First-Line	
Dose-Adjusted Etoposide + Prednisone + Vincristine + Cyclophosphamide + Doxorubicin + Rituximab (DA-EPOCH-R)	1127
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) ± Rituximab (CHOP ± Rituximab)	1134

Chapter 22. HODGKIN LYMPHOMA

Induction • First-Line

Doxorubicin (Adriamycin) + Bleomycin + Vinblastine + Dacarbazine (ABVD)	1141
Brentuximab Vedotin + Doxorubicin + Vinblastine + Dacarbazine (A+AVD)	1144
Bleomycin + Etoposide + Doxorubicin (Adriamycin) + Cyclophosphamide + Vincristine (Oncovin) + Procarbazine + Prednisone (BEACOPP)	1149
Stanford V	Online

Induction • Salvage

Dexamethasone + Cytarabine (Ara-C) + Cisplatin (DHAP)	1151
Ifosfamide + Carboplatin + Etoposide (ICE)	1153
Ifosfamide + Gemcitabine + Vinorelbine (IGEV)	1155
High-Dose Ifosfamide + Etoposide (VP16) + Epirubicin (IVE)	1157
Gemcitabine + Vinorelbine + Doxorubicin, Liposomal (GVD)	Online
Dexamethasone + Carmustine (BCNU) + Etoposide + Cytarabine (Ara-C) + Melphalan (DEXA-BEAM)	Online

High-Dose Chemotherapy Conditioning

Carmustine (BCNU) + Etoposide + Cytarabine (Ara-C) + Melphalan (BEAM)	Online
Cyclophosphamide + Carmustine (BCNU) + Etoposide (VP16) (CBV)	Online

Consolidation After Autologous Hematopoietic Stem Cell Transplant

Brentuximab Vedotin	1158
---------------------	------

Subsequent Therapy

Brentuximab Vedotin	1161
Nivolumab	1164
Pembrolizumab	1170
Gemcitabine	Online
Vinorelbine	Online
Bendamustine	Online

Chapter 23. LUNG CANCER

Stage III NSCLC • Consolidation After Chemoradiation

Durvalumab	1180
------------	------

Advanced Squamous NSCLC • First-Line

Pembrolizumab + Paclitaxel/Nab-Paclitaxel + Carboplatin	1188
---	------

Advanced Non-Squamous NSCLC • First-Line

Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed	1198
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel (ABCP)	1210
Paclitaxel + Carboplatin + Bevacizumab	1225
Cisplatin + Pemetrexed	1227

XX CONTENTS: REGIMENS LISTED BY TYPE OF CANCER

Advanced NSCLC • First-Line

Pembrolizumab	1228
Paclitaxel + Carboplatin	1236
Gemcitabine + Cisplatin	1238
Docetaxel + Cisplatin	1240
Vinorelbine + Cisplatin	1242
Weekly Nab-Paclitaxel + Carboplatin	1243
Vinorelbine	1247

Advanced Non-Squamous NSCLC • Maintenance

Pemetrexed	1248
------------	------

Advanced NSCLC • Subsequent Therapy

Ramucirumab + Docetaxel	1251
Docetaxel	1255
Nivolumab	1256
Pembrolizumab	1263
Atezolizumab	1270
Pemetrexed	1277

Advanced NSCLC • EGFR Mutated • First-Line

Osimertinib	1278
Gefitinib	1282
Erlotinib	1285
Afatinib	Online

Advanced NSCLC • EGFR Mutated • Subsequent Therapy

Osimertinib	1290
-------------	------

Advanced NSCLC • ALK-Rearranged • First-Line

Alectinib	1294
Brigatinib	1297
Ceritinib	1303
Crizotinib	1307

Advanced NSCLC • ALK-Rearranged • Subsequent Therapy

Brigatinib	1311
Lorlatinib	1317

Limited-Stage SCLC • Chemoradiotherapy

Etoposide + Cisplatin with Concurrent Thoracic Radiation Therapy	1324
--	------

Extensive-Stage SCLC • First-Line

Atezolizumab + Carboplatin + Etoposide	1326
--	------

Extensive Stage SCLC • Subsequent Therapy

Topotecan	1335
Pembrolizumab	1336

Chapter 24. MELANOMA

Adjuvant

Nivolumab	1345
Pembrolizumab	1351
Dabrafenib + Trametinib	1357
Interferon Alfa-2b	1361
Pegylated Interferon Alfa-2b	1363

Metastatic	
Ipilimumab	1365
Pembrolizumab	1372
Nivolumab	1379
Nivolumab + Ipilimumab	1385
Metastatic • BRAF V600E Targeted Therapy	
Vemurafenib	1392
Vemurafenib + Cobimetinib	1393
Dabrafenib + Trametinib	1397
Encorafenib + Binimetinib	1402
Metastatic • Cytotoxic Therapy	
Dacarbazine (DTIC)	1409
Temozolomide	1410
Carboplatin + Paclitaxel	1411

Chapter 25. MESOTHELIOMA

Advanced Disease • First-Line	
Pemetrexed + Cisplatin	1417
Pemetrexed + Carboplatin	1418
Gemcitabine + Cisplatin	1422
Bevacizumab + Gemcitabine + Cisplatin	1423
Bevacizumab + Pemetrexed + Cisplatin	1427
Advanced Disease • Subsequent Therapy	
Pembrolizumab	1431
Nivolumab	1438
Nivolumab + Ipilimumab	1447
Mesothelioma (Peritoneal) Resectable Disease	
Intraperitoneal Cisplatin + Paclitaxel	1454

Chapter 26. MULTIPLE MYELOMA

Transplant-Eligible • First-Line Induction	
Bortezomib + Lenalidomide + Dexamethasone (VRd)	1464
Carfilzomib + Lenalidomide + Dexamethasone (CRd)	1468
Cyclophosphamide + Bortezomib + Dexamethasone (CyBorD)	1472
Bortezomib + Thalidomide + Dexamethasone (VTD)	1475
Bortezomib + Doxorubicin + Dexamethasone (PAD)	1478
Lenalidomide + Low-Dose Dexamethasone (Rd)	1482
Bortezomib + Dexamethasone	1485
Bortezomib + Thalidomide + Dexamethasone + Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide (VTD-PACE)	1488
Thalidomide + Dexamethasone	Online
Carfilzomib + Thalidomide + Low-Dose Dexamethasone (KTd)	Online
Transplant-Eligible or Transplant-Ineligible • First-Line Induction	
Ixazomib + Lenalidomide + Dexamethasone (IRd)	1495
High-Dose Chemotherapy (Before Autologous Stem Cell Transplantation)	
High-Dose Melphalan	Online
Transplant-Ineligible • First-Line Induction	
Lenalidomide + Dexamethasone (Rd)	1501

XXII CONTENTS: REGIMENS LISTED BY TYPE OF CANCER

Modified Lenalidomide + Bortezomib + Dexamethasone (RVD-lite)	1506
Daratumumab + Lenalidomide + Dexamethasone (DRd)	1511
Melphalan + Prednisone + Lenalidomide (MPR)	1519
Bortezomib + Melphalan + Prednisone (VMP)	1522
Daratumumab + Bortezomib + Melphalan + Prednisone (D-VMP)	1525
Melphalan + Prednisone + Thalidomide (MPT)	1534
Carfilzomib + Cyclophosphamide + Dexamethasone (CCyd)	1537
Maintenance Therapy	
Lenalidomide + Bortezomib + Dexamethasone (RVD)	1542
Bortezomib	1547
Lenalidomide	1550
Thalidomide	Online
Subsequent Therapy	
Daratumumab	1557
Daratumumab + Lenalidomide + Low-Dose Dexamethasone (D-Rd)	1562
Daratumumab + Bortezomib + Dexamethasone (D-Vd)	1570
Isatuximab + Pomalidomide + Dexamethasone (Isa-Pd)	1576
Elotuzumab + Lenalidomide + Dexamethasone (Elo-Rd)	1583
Elotuzumab + Pomalidomide + Dexamethasone (Elo-Pd)	1589
Carfilzomib + Dexamethasone (Kd)	1597
Carfilzomib + Lenalidomide + Dexamethasone (KRd)	1601
Ixazomib + Lenalidomide + Dexamethasone (IRd)	1607
Pomalidomide + Dexamethasone (Pd)	1613
Pomalidomide + Cyclophosphamide + Prednisone (PCP)	1620
Selinexor + Dexamethasone	1624
Lenalidomide + Dexamethasone	1629
Dexamethasone + Cyclophosphamide + Etoposide + Cisplatin (DCEP)	1633
Liposomal Doxorubicin + Bortezomib	1636
Carfilzomib	Online
Weekly Carfilzomib	Online
Bendamustine + Lenalidomide + Dexamethasone (BLD)	Online
Bendamustine + Pomalidomide + Dexamethasone (BPD)	Online
Chapter 27. MYELOYDYSPLASTIC SYNDROMES	
Decitabine	1645
Decitabine + Cedazuridine	1648
Azacitidine	1654
Lenalidomide	1657
Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine) (ATG)	1661
Luspatercept	1664
Chapter 28. MYELOPROLIFERATIVE NEOPLASMS	
Polycythemia Vera (PV) and/or Essential Thrombocythemia (ET)	
Phlebotomy (PV)	1678
Aspirin (PV and ET)	1679
Hydroxyurea (PV and ET)	1681
Anagrelide (PV and ET)	1683
Interferon Alfa-2b (PV and ET)	1685
Busulfan (ET)	1688

Ruxolitinib (PV)	1690
Pipobroman (PV and ET)	Online
Primary Myelofibrosis	
Low-Dose Thalidomide + Prednisone	1694
Lenalidomide	1696
Hydroxyurea	1698
Ruxolitinib	1700
Fedratinib	1708

Chapter 29. NEUROENDOCRINE TUMORS

Metastatic • Locally Advanced

Short-Acting Octreotide Acetate	1717
Long-Acting Octreotide	1719
Lanreotide	1721
Streptozocin + Fluorouracil	1723
Streptozocin + Doxorubicin	1725
Sunitinib Malate	1726
Everolimus	1730
Cisplatin + Etoposide	1733
Capecitabine + Temozolomide	1735
Lutetium Lu 177 Dotatate	1738
Temozolomide	Online

Chapter 30. NON-HODGKIN LYMPHOMA

DLBCL • First Line

CHOP + Rituximab	1752
------------------	------

DLBCL (Older Patients) • First Line

Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (R-Mini-CHOP)	1755
Rituximab + Cyclophosphamide + Epirubicin + Vinblastine + Prednisone (R-Mini-CEOP)	1760
Rituximab + Gemcitabine + Cyclophosphamide + Vincristine + Prednisolone (R-GCVP)	1763
Rituximab + Bendamustine (R-Benda)	1768
Rituximab + Gemcitabine + Oxaliplatin (R-Gem-Ox)	1772
Rituximab + Cyclophosphamide + Pegylated Liposomal Doxorubicin + Vincristine + Prednisone (R-CDOP)	Online

DLBCL (Primary Mediastinal DLBCL, Double Hit Lymphoma, and Triple Hit Lymphoma)

Dose-Adjusted Etoposide + Prednisone + Vincristine + Cyclophosphamide + Doxorubicin + Rituximab (DA-EPOCH-R)	1775
--	------

DLBCL • Subsequent Therapy

Rituximab + Ifosfamide + Carboplatin + Etoposide (RICE)	1780
Rituximab + Dexamethasone + Cytarabine + Cisplatin (R-DHAP)	1782
Rituximab + Etoposide + Methylprednisolone + Cytarabine + Cisplatin (R-ESHAP)	Online
Gemcitabine + Dexamethasone + Cisplatin + Rituximab (GDP-R)	Online

DLBCL • Subsequent Therapy, Ineligible for Autologous Stem Cell Transplant or Relapsed/Refractory

Rituximab + Lenalidomide (R ²)	1786
Bendamustine + Rituximab (BR)	1790
Tafasitamab + Lenalidomide	1795
Polatuzumab Vedotin + Bendamustine + Rituximab (Pola-BR)	1802
Selinexor	1807

XXIV CONTENTS: REGIMENS LISTED BY TYPE OF CANCER**Follicular Lymphoma • First Line**

Rituximab + Cyclophosphamide + Vincristine + Prednisone (R-CVP)	1811
Cyclophosphamide + Vincristine + Prednisone (CVP) + Obinutuzumab	1813
Bendamustine + Rituximab (BR)	1819
Bendamustine + Obinutuzumab	1824
Lenalidomide + Rituximab (R ²)	1831
Cyclophosphamide + Vincristine + Prednisone (CVP)	Online

Follicular Lymphoma • First Line or Subsequent Therapy

Rituximab	1836
Extended-Schedule Rituximab	1837

Follicular Lymphoma • Maintenance Therapy

Maintenance Rituximab	1839
-----------------------	------

Follicular Lymphoma • Subsequent Therapy

Idelalisib	1841
Copanlisib	1845
Duvelisib	1849
Tazemetostat	1852
Obinutuzumab + Lenalidomide (Obi-Len)	Online
Bortezomib	Online

Mantle Cell Lymphoma • First Line

Nordic Regimen: (R)-Maxi-CHOP Alternating with (R)-HiDAC	1856
Rituximab + Hyperfractionated Cyclophosphamide + Vincristine + Doxorubicin + Dexamethasone (R-Hyper-CVAD) Alternating with Rituximab + Methotrexate + Cytarabine (R-MC)	1862
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (R-CHOP) then Rituximab + Dexamethasone + Cytarabine + Cisplatin (R-DHAP)	1871
Bendamustine + Rituximab then Cytarabine + Rituximab (BR → R-Cytarabine)	1877

Mantle Cell Lymphoma • First Line (Less Aggressive)

Bortezomib + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone (VR-CAP)	1884
Lenalidomide + Rituximab (R ²)	1888
Rituximab + Bendamustine + Cytarabine (R-BAC)	1894

Mantle Cell Lymphoma • Subsequent Therapy

Lenalidomide	1898
Ibrutinib	1902
Acalabrutinib	1905
Zanubrutinib	1908
Venetoclax + Ibrutinib	1911
Bortezomib	Online
Temsirolimus	Online

Peripheral T-Cell Lymphoma • First Line

Brentuximab Vedotin + Cyclophosphamide + Doxorubicin + Prednisone (A+CHP)	1919
Cyclophosphamide + Doxorubicin + Vincristine + Etoposide + Prednisolone (CHOEP)	1923

Peripheral T-Cell Lymphoma • Subsequent Therapy

Romidepsin	1925
Pralatrexate	1929

Belinostat	1933
Brentuximab Vedotin	1935
Bendamustine	1938
Burkitt Lymphoma • First Line	
Dose-Adjusted Etoposide + Prednisone + Vincristine + Cyclophosphamide + Doxorubicin + Rituximab (DA-EPOCH-R)	1940
Cyclophosphamide, Vincristine + Doxorubicin + Methotrexate (CODOX-M)/Ifosfamide + Etoposide + Cytarabine (IVAC)	1945
Rituximab + Hyperfractionated Cyclophosphamide + Vincristine + Doxorubicin + Dexamethasone (R-Hyper-CVAD) Alternating with Rituximab + Methotrexate + Cytarabine (R-MC)	1950

Chapter 31. OVARIAN CANCER

First-Line Intraperitoneal Chemotherapy	
Intraperitoneal Cisplatin and Paclitaxel	1964
Recurrent • Platinum-Sensitive • First-Line	
Carboplatin + Paclitaxel	1967
Cisplatin + Paclitaxel	1969
Carboplatin + Weekly (Dose-Dense) Paclitaxel	1970
Cisplatin + Cyclophosphamide	Online
Recurrent • Platinum-Sensitive	
Platinum Retreatment (Cisplatin or Carboplatin)	1973
Gemcitabine + Carboplatin	1976
Gemcitabine + Carboplatin + Bevacizumab	1978
Liposomal Doxorubicin + Carboplatin	1982
Carboplatin + Docetaxel	1984
Weekly Carboplatin + Docetaxel	1986
Cisplatin + Gemcitabine	1989
Recurrent • Platinum-Sensitive • Maintenance	
Niraparib	1991
Olaparib	1993
Rucaparib	1995
Recurrent Platinum Refractory/Platinum Resistant	
Docetaxel	1998
Fluorouracil + Leucovorin	2000
Gemcitabine	2001
Liposomal Doxorubicin	2002
Vinorelbine	2003
Paclitaxel (24-Hour Paclitaxel Infusion Every 3 Weeks or Weekly Paclitaxel)	2004
Topotecan	2006
Liposomal Doxorubicin + Bevacizumab	2007
Olaparib	2011
Topotecan HCL + Bevacizumab	2013
Weekly Paclitaxel + Bevacizumab	2016
Weekly Paclitaxel + Pazopanib	Online
Oral Etoposide	Online
Tamoxifen	Online

Chapter 32. PANCREATIC CANCER

Adjuvant

Modified FOLFIRINOX	2026
Gemcitabine + Capecitabine	2032
Gemcitabine + Nab-Paclitaxel	2039

Metastatic • First Line

FOLFIRINOX	2045
Gemcitabine	2050

Metastatic • Subsequent Therapy

Liposomal Irinotecan + Fluorouracil + Leucovorin	2051
Gemcitabine + Cisplatin	2062
Gemcitabine + Nab-Paclitaxel + Cisplatin	2064
Oxaliplatin + Folinic Acid (Leucovorin) + Fluorouracil (OFF)	2068
FOLFIRI-I	Online
FOLFOX	Online
Mitomycin + Irinotecan + Cisplatin (MIC)	Online

Chapter 33. PHEOCHROMOCYTOMA

Advanced/Unresectable or Metastatic

Cyclophosphamide + Vincristine + Dacarbazine	2074
--	------

Chapter 34. PROSTATE CANCER

Locally Advanced • Metastatic

Hormonal Agents	2081
-----------------	------

Non-Metastatic • Castration-Resistant

Apalutamide	2083
Enzalutamide	2087
Darolutamide	2090

Metastatic • Hormone-Sensitive

Abiraterone + Prednisone	2093
Apalutamide	2096
Docetaxel	2100
Enzalutamide	2104

Metastatic • Castration-Resistant • First-Line

Sipuleucel-T	2107
Abiraterone	2109
Enzalutamide	2112
Docetaxel + Prednisone	2114
Mitoxantrone + Prednisone	Online

Metastatic • Castration-Resistant • Subsequent Therapy

Abiraterone	2115
Enzalutamide	2120
Cabazitaxel + Prednisone	2123
Radium-223	2125

Chapter 35. RENAL CELL CANCER

High-Risk • Localized Clear-Cell • Adjuvant Therapy

Sunitinib	2138
-----------	------

Metastatic • Clear-Cell • First-Line	
Pembrolizumab + Axitinib	2143
Nivolumab + Ipilimumab	2153
Avelumab + Axitinib	2161
Pazopanib	2171
Sunitinib (4 Weeks On/2 Weeks Off)	2177
Sunitinib (2 Weeks On/1 Week Off)	2182
Cabozantinib	2186
Metastatic • Clear-Cell • Subsequent Therapy	
Lenvatinib + Everolimus	2190
Nivolumab	2197
Temsirrolimus	2204
Axitinib	2207
Everolimus	Online
Bevacizumab	Online
Metastatic • Non-Clear Cell • First-Line	
Sunitinib	2211
Cabozantinib	2213
Everolimus	Online
Metastatic • Non-Clear Cell • Subsequent Therapy	
Lenvatinib + Everolimus	2218
Nivolumab	2223
Pazopanib	2229
Axitinib	2234
Temsirrolimus	2238
Bevacizumab	Online
Chapter 36. SARCOMAS	
Osteosarcoma • First-Line	
High-Dose Methotrexate + Doxorubicin + Cisplatin (MAP, EURAMOS-1)	2249
Doxorubicin + Cisplatin + Ifosfamide (API-AP)	2256
Osteosarcoma • Recurrent or Progressive	
Etoposide + High-Dose Ifosfamide	2261
Gemcitabine + Docetaxel	2264
Regorafenib	2267
Cabozantinib	2274
Sorafenib	Online
Ewing Sarcoma • Newly Diagnosed	
Interval Compressed Vincristine + Doxorubicin + Cyclophosphamide (VDC) alternating with Ifosfamide + Etoposide (IE) (AEWS0031 Protocol)	2279
Vincristine + Ifosfamide + Doxorubicin + Etoposide (VIDE) then Vincristine + Dactinomycin + Ifosfamide (VAI) then Vincristine + Dactinomycin + Cyclophosphamide (VAC) (EURO-EWING99-R1 Protocol)	2285
Vincristine + Cyclophosphamide + Doxorubicin or Dactinomycin (VACD) alternating with Ifosfamide + Etoposide (IE) (INT-0091 Protocol)	Online
Ewing Sarcoma • Recurrent/Refractory	
Cyclophosphamide + Topotecan	2291
Temozolomide + Irinotecan (5 days x 2 dosing)	2293
Temozolomide + Irinotecan (5 days) ± Vincristine	2296

XXVIII CONTENTS: REGIMENS LISTED BY TYPE OF CANCER

High-Dose Ifosfamide	2299
Trabectedin + Irinotecan	2302
Cabozantinib	Online
Rhabdomyosarcoma • Non-metastatic • Low Risk Subset A • Previously Untreated	
Vincristine + Dactinomycin (VA) (D9602)	2316
Vincristine + Dactinomycin + Cyclophosphamide (VAC) followed by VA (ARST0331)	2320
Rhabdomyosarcoma • Non-metastatic • Low Risk Subset B • Previously Untreated	
Vincristine + Dactinomycin + Cyclophosphamide (VAC) (D9602)	2324
Rhabdomyosarcoma • Non-metastatic • Not Low Risk • Previously Untreated	
Vincristine + Dactinomycin + Cyclophosphamide (VAC) (D9803) ± Maintenance Therapy (RMS 2005)	2330
Vincristine + Dactinomycin + Cyclophosphamide (VAC)/Vincristine + Irinotecan (VI) (ARST0531) ± Maintenance Therapy (RMS 2005)	2336
Ifosfamide + Vincristine + Dactinomycin (IVA) plus Vinorelbine + Cyclophosphamide Maintenance Therapy (RMS 2005)	2342
Vincristine + Dactinomycin + Cyclophosphamide (VAC) (IRS-IV) ± Maintenance Therapy (RMS 2005)	Online
Rhabdomyosarcoma • Metastatic • Previously Untreated	
Vincristine + Dactinomycin + Cyclophosphamide (VAC) (IRS-IV)	2349
Intensive Multiagent Therapy (ARST0431)	2354
Rhabdomyosarcoma • Relapsed/Refractory	
Vinorelbine + Cyclophosphamide + Temozolomide	2362
Vinorelbine	2367
Vincristine + Irinotecan + Temozolomide	2370
Topotecan + Cyclophosphamide	Online
Vinorelbine + Low-Dose Oral Cyclophosphamide	Online
Soft-Tissue Sarcoma • Metastatic or Unresectable	
Doxorubicin	2374
Doxorubicin + Ifosfamide (AI)	2376
Epirubicin + Ifosfamide	2379
Ifosfamide	Online
Doxorubicin + Dacarbazine (AD)	Online
Soft-Tissue Sarcoma • Recurrent or Progressive	
Gemcitabine + Docetaxel or Gemcitabine Alone	2382
Trabectedin (for liposarcoma or leiomyosarcoma)	2385
Gemcitabine + Docetaxel (for leiomyosarcoma)	2388
Eribulin	2391
Gemcitabine + Dacarbazine	Online
Dermatofibrosarcoma Protuberans (DFSP) with PDGFB Rearrangement	
Imatinib	2395
Epithelioid Sarcoma with INI1 Loss • Unresectable	
Tazemetostat	2398
Desmoid Tumors • Prior Chemotherapy	
Pazopanib	2402
Sorafenib	2412
Malignant Peripheral Nerve Sheath Tumors	
Ifosfamide + Doxorubicin and Ifosfamide + Etoposide	2418
Inflammatory Myofibroblastic Tumors	
Crizotinib	2422

Undifferentiated Pleomorphic Sarcoma	
Pembrolizumab	2428
Gastrointestinal Stromal Tumor (GIST) • Adjuvant Therapy	
Imatinib for 1 Year	2437
Imatinib for 3 Years	2440
Imatinib for 5 Years	2443
Gastrointestinal Stromal Tumor (GIST) • Unresectable	
Imatinib	2445
Sunitinib	2448
Regorafenib	2456
Ripretinib	2459
Avapritinib	2463
Chapter 37. TESTICULAR CANCER	
First-Line	
Etoposide + Cisplatin (EP)	2472
Bleomycin + Etoposide + Cisplatin (BEP)	2474
Etoposide + Ifosfamide + Cisplatin (VIP)	2476
Subsequent Therapy	
Paclitaxel + Ifosfamide + Cisplatin (TIP)	2478
Vinblastine + Ifosfamide + Cisplatin (VeIP)	2480
Chapter 38. THYMIC MALIGNANCIES	
Advanced Disease • First-Line	
Doxorubicin + Cisplatin + Vincristine + Cyclophosphamide (ADOC)	2485
Cisplatin + Etoposide	2486
Cisplatin + Doxorubicin + Cyclophosphamide (PAC)	2487
Paclitaxel + Carboplatin	2488
Advanced Disease • Second-Line	
Capecitabine + Gemcitabine	2491
Sunitinib	2494
Octreotide ± Prednisone	Online
Chapter 39. THYROID CANCER	
Advanced • Radioactive Iodine-Refractory • Differentiated	
Sorafenib Tosylate	2507
Lenvatinib	2511
Advanced • Medullary	
Vandetanib	2515
Cabozantinib	2520
Anaplastic	
Doxorubicin and Radiation with Debulking Surgery	2524
96-Hour Continuous-Infusion Paclitaxel or Weekly Paclitaxel	2525
Dabrafenib + Trametinib	2527
RET-Mutant Medullary • RET Fusion-Positive Thyroid Cancer	
Selpercatinib	2531